Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The New York Times just published my letter in response to an article, "What could happen if there's no more Covid-19 funding".

In a controlled clinical trial at Houston Methodist Hospital, a drug named Aviptadil, the "vip" part of the name stands for "vaso-intestinal peptide, has proven to be remarkably effective in treating critically ill Covid 19 patients.

Patients treated with intravenous Aviptadil-VIP were followed for at least 60 days after ICU admission. They were compared with 24 individuals with comparable COVID-19 and co-morbidities, who received only standard-of-care treatment. Of the 21 patients treated with Aviptadil, 19 survived to day 28, 17 survived to day 60 compared to only five survivors of the 24 individuals in the standard-therapy group (81% vs. 21%; p < 0.0001). Improved radiographic appearance was seen in both lungs of 17 VIP treated patients but only one lung of two VIP treated patients who subsequently died. Four out of five patients treated with Aviptadil on Extracorporeal Membrane Oxygenation were successfully de-cannulated and survived. In comparison, only three out of 13 standard-therapy patients survived.

Initial release of the data revealed increased survival rates that correlated to a significant reduction in plasma IL-6 and improved lung-surfactant production.", has shown to be effective.

Currently in the TESICO trial in the USA, Aviptadil, produced by Relief Therapeutics with their partner NeuroRx, also needs continued funding for this trial.
Does anyone read those letters?

~ Posted by Thomas, Y@h00 RLFTG